Abstract
Anhedonia, the diminished capacity to experience pleasure, is a hallmark symptom of both Major Depressive Disorder (MDD) and schizophrenia. This study investigates the distinct manifestations of anhedonia—specifically anticipatory versus consummatory pleasure—across these disorders. Results indicate that while both groups suffer significant impairments, anhedonia appears to be a fluctuating "state" in MDD, correlating with illness progression, whereas it serves as a stable "trait" in schizophrenia, particularly regarding anticipatory pleasure.
Introduction
Modern neuropsychology distinguishes between two phases of pleasure: anticipatory pleasure (the "wanting" or excitement for a future reward) and consummatory pleasure (the "liking" or in-the-moment enjoyment). While anhedonia is central to both MDD and schizophrenia, previous research has been inconsistent regarding which phase is most affected in each disorder. This study clarifies these distinctions within a large Chinese cohort, exploring whether these deficits are stable traits or clinical states that shift with illness severity.
Methods and Datasets
The researchers conducted a multi-center study involving 790 participants recruited from six hospitals in China. The cohort included 176 patients with MDD, 346 with schizophrenia, and 268 healthy controls.
To assess pleasure, the Temporal Experience of Pleasure Scale (TEPS) was utilized, providing separate scores for anticipatory (TEPS-ANT) and consummatory (TEPS-CON) components. Clinical severity was measured using the Hamilton Depression Rating Scale (HAMD-17) for MDD and the Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Key Results
The study revealed significant impairments in both patient groups compared to healthy controls. Notably, MDD patients exhibited more profound deficits in both types of pleasure than patients with schizophrenia.
- Significant Impairment: Both MDD and schizophrenia groups scored significantly lower than healthy controls on both TEPS subscales ($P < 0.001$).
- Severity in MDD: MDD patients reported lower subjective pleasure scores than those with schizophrenia, suggesting a more intense experience of anhedonia during depressive episodes.
- Correlation with Clinical Variables: In the MDD group, both anticipatory and consummatory pleasure scores were negatively correlated with the duration of illness and the number of hospital admissions. In contrast, for schizophrenia patients, anticipatory pleasure (TEPS-ANT) showed no significant correlation with clinical variables, indicating its stability over time.
Discussion: State vs. Trait
The most significant finding of this research is the conceptual distinction between anhedonia in these two disorders:
- MDD as a "State": In depression, anhedonia scales with the severity and duration of the illness. This suggests that as the disease progresses or worsens, the capacity for pleasure further diminishes, acting as a marker of the current clinical state.
- Schizophrenia as a "Trait": In schizophrenia, particularly for anticipatory pleasure, the deficit remains stable regardless of clinical fluctuations or illness duration. This suggests that the inability to look forward to rewards is a core, baseline feature (a trait) of the disorder's pathology.
Conclusion and Future Work
While both disorders involve a breakdown in the pleasure response, the underlying nature of these deficits differs. Future research should employ longitudinal designs to track these symptoms over time and investigate how different medication classes—such as typical versus atypical antipsychotics—influence the "wanting" and "liking" systems in the brain.
Summary updated